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Compassionate use of amphotericin B lipid complex 
(Abelcet) in life-threatening fungal infections: report 
of 30 courses 
Ph. Clevenbergh ', 
E.  Serruys* and]. 
EJacobs', A. Kentos', B. Byl', L. Coll&non', M.  Moermanl, 
I? Thys' 
Infectious Diseases Department and 'Microbiology Department, Erasme University Hospital, 
Universid Libre de Bruxelles, Brussels, Belgium 
Objective: To report a single-center experience of compassionate use of arnphotericin B lipid complex (ABLC) in 
patients with proven or suspected fungal infection who were or would have been unable to tolerate conventional 
amphotericin B. 
Methods: Twenty-eight patients receiving 30 courses of ABLC for 22 proven invasive mycosis episodes (11 
aspergillosis, seven candidosis, four miscellaneous) and eight suspected episodes are described. Seven patients were 
given ABLC first-line therapy because of conditions precluding the use of amphotericin B deoxycholate (Am B). Twenty- 
one patients, initially given Am B, were shifted to ABLC because of failure in four, nephrotoxicity of AM B alone or in 
combination with another drug in 15, and acute side effects in two. The initial dose of ABLC was 5 mg/kg per day; this 
could be lowered to 3 mg/kg per day or transiently interrupted in cases of impairment of renal function. 
Results: A mean cumulative dose of 6107 mg (660-16 050) was given over a mean duration of 22 days (4-49). Clinical 
response rate was 63% (14/22), with mycologic eradication in 37% (9/17) in proven infections. For proven aspergillosis, 
corresponding rates were 54% (6/11) and 20% (2/10), and in proven candidosis 71% (5/7) and 60% (3/5), respectively. 
Twenty-one courses were complicated by one or more side effects: fever and chills (111, impairment of renal function 
requiring a transient reduction of drug dosage (14), hypotension (I). However, for the whole group, creatinine clearance 
before and after 2, 4 and 6 weeks of treatment remained quite stable. 
Conclusions: ABLC, with its low toxicity, enabled us to treat patients who were or would have been unable to tolerate 
an efficacious dose of Am B. No conclusions about efficacy can be drawn from this small-size, compassionate study. 
Well-designed studies to compare efficacy and safety of conventional amphotericin B and the various lipidic formulations 
should be implemented. 
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INTRODUCTION 
Invasive fungal infections have a poor prognosis due 
to late diagnosis, uncontrolled underlying &ease, and 
a lack of effective non-toxic treatment. Until recently, 
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amphotericin B (Am B) has been the mainstay in the 
treatment of these infections. However its use is 
hampered by severe side effects such as fever, chlls and 
hypotension (which are infusion-related) and nephro- 
toxicity [l]. This last frequently limits the therapeutic 
utility of the deoxycholate micelle formulation of 
amphotericin B. Increases in blood urea nitrogen and 
creatinine levels occur in over 80% of patients receiving 
amphotericin B [2].  Most of the patients with an 
already compromised renal function would not be 
able to tolerate the necessary dose of conventional 
amphotericin B. By contrast, lipid-associated ampho- 
tericin B has demonstrated reduced toxicity, allowing 
the use of larger doses, and increasing the therapeutic 
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index [3-51. In experimental animal models, ampho- 
tericin B lipid complex (ABLC) was four-fold less 
effective than or equal to equivalent dosages of Am B. 
In comparative animal studies, ABLC was more effi- 
cacious than Am B in the treatment of severe acute 
aspergillosis, cryptococcosis and candidosis [6]. Clinical 
experience with ABLC is limited. In a multicentric 
series of 228 cases [7] of invasive fungal infections 
treated with ABLC, 69% had a clinical response which 
was mycologically confirmed in 55%, and the drug was 
well tolerated. The most common side effects were 
chills, fever and nausea. Mean serum creatinine levels 
even decline during therapy, particularly in patients 
with pre-existing renal dysfunction. In a series of bone 
marrow transplant recipients with life-threatening 
systemic mycoses [8], a 53% clinical response rate 
and 50% mycologic eradication were reported. A 
decline in the serum creatinine levels was also observed. 
Prolonged treatment with very high cumulative doses 
of ABLC (22.3-73.6 g) given over a prolonged period 
(mean 53.8 weeks) has been shown to be of limited 
toxicity in a s m a l l  series [9] .  The creatinine level rose 
only fiom 1 mg/dL at the beginning, to 1.5 mg/dL at 
the end of the therapy. Amphotericin B lipid complex 
was made available in a compassionate program in our 
institution to treat patients with proven or suspected 
invasive fungal disease, intolerant of or failing conven- 
tional amphotericin B. We describe 28 patients receiving 
30 courses of ABLC. 
METHODS 
Abelcet, the ABLC preparation from the Liposome 
Company, Inc., Princeton, NJ, was provided as a lyo- 
phhzed powder. The drug was reconstituted according 
to the manufacturer’s instructions and infused over 2 h. 
Infusion time was extended to 4 h in cases of infusion- 
related fever and ch&. The initial dose was 5 mg/kg 
per day. In cases of increase of creatinine during ABLC 
treatment, doses were reduced to 3 mg/kg per day 
or discontinued for a few days until renal function 
improved. 
Criteria for diagnosis of fungal disease 
Invasive candidosis was considered as proven in the case 
of recovery of Candida organisms in at least one blood 
culture or in material fkom deep tissue sites or &om 
body spaces that are normally sterile, or when Candida 
spp. were recovered as a single pathogen and in high 
quantity from an abdominal drain in infected post- 
abdominal surgical patients unresponsive to broad- 
spectrum antibiotics. 
Invasive aspergillosis was defined as proven when 
Aspergillus spp. were identified by histologic examin- 
ation and culture of tissue specimens or, in cases of 
febrile neutropenia, when Aspergilhs spp. were isolated 
h m  the respiratory secretions of a patient with lung 
infiltrates unresponsive to broad-spectrum antibiotics. 
Invasive aspergdlosis was defined a s  probable in febrile 
neutropenic patients with pulmclnary infiltrates un- 
responsive to antibiotics without identification of 
Aspergillus, and in non-neutropenic immunosuppressed 
patients with lung infiltrates unresponsive to anti- 
microbial treatment when Aspergillus spp. were recovered 
fiom bronchoalveolar lavage. 
Criteria for side effects of Am B or AElLC 
Renal dyshnction due to Am B or as other cause was 
considered if baseline creatinine clearance was below 
70 ml/min secondary to Am B administration or other 
drug toxicity. Renal toxicity of Pun B also included 
tubular lesions with electrolyte imbalance. Known 
drugs or conditions precluding the use of full doses of 
Am B, such as cyclosporin therapy, septic shock, or 
multiple myeloma, were other criteria for entry to the 
study. We defined nephrotoxicity fiom ABLC treat- 
ment as an increase in serum creatinine level >25% 
compared to the lowest level obtained at the beginning 
or during therapy before the event, or severe electrolyte 
imbalance. 
Acute side effects were reported as fever or chills 
apparently infusion-related occurri.ng during Am B or 
ABLC treatment. 
Criteria for clinical evaluation 
Failure of Am B was defined as the persistence or 
progression of signs and symptoms considered to be due 
to hngal infection after at least 5 days of treatment with 
Am B. 
Clinical cure or improvement were defined as 
elimination or improvement of pretreatment signs and 
symptoms attributable to the infection and survival at 
1 month after treatment completion. Clinical failure 
was defined as evolution to death, whatever the cause. 
Criteria for mycologic evaluation 
For mycologic evaluation, eradicat:ion was considered 
when a l l  previously positive cultures and/or micro- 
scopic examinations had become negative for the 
fungal pathogen, and persistence when cultures and/ 
or microscopic examinations had remained positive 
despite treatment. The mycologic data were considered 
not evaluable when data were insufficient to allow 
assessment of response for whatever reason. 
Patients 
Patients with proven or probable hngal infection 
intolerant of or unresponsive to Am B, or with renal 
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failure of other cause precluding the use of Am B, were 
given ABLC in a compassionate, open label study. 
This study was conducted at a single institution over 
a 2-year period. Informed consent was obtained h-om 
every subject or legal representative prior to inclusion. 
The study was approved by the Ethical Committee of 
the hospital. 
Thirty patients were treated with ABLC for 32 
episodes of fungal infection. Two patients died after 
having received only one dose of ABLC and were 
excluded h-om the analysis. Their deaths were unrelated 
to ABLC therapy. The 28 other patients were treated 
with a t  least four doses of ABLC for 30 episodes of 
fungal infections. There were 18 males and 10 females 
of a mean age of 45 years (range 15-74). The under- 
lying condition, fungal disease, mode of diagnosis, 
previous therapy, reason for inclusion, ABLC total dose 
and duration, creatinine clearance at entry and study 
end, as well as clinical and microbiological evolution 
are displayed in Table 1. 
First-line ABLC therapy was considered for seven 
patients. Among them, four had pre-existing renal 
failure (mean creatinine clearance 27 mL/min (range 
22-32 ml/min) and three (mean creatinine clearance: 
130 d / m i n  at entry) presented with cyclosporin 
treatment, multiple myeloma, and septic shock, respec- 
tively. 
Twenty-one patients, initially treated with Am B 
(mean cumulative dose 543 mg; range 50-1850 mg) 
received ABLC as second-line treatment, because of 
failure in four patients, nephrotoxicity in 1.5 patients 
and infusion-related side effects in two patients. 
Of the four patients considered to have failed to 
respond to conventional amphotericin B, three had 
proven invasive aspergillosis, and one had fusaremia. 
The Aspergillus-infected patients with progressive pul- 
monary infiltrate while on Am B had received 16, 
14 and 7 mg/kg cumulative doses ofAm B respectively, 
and the fusaremic patient with persistent fever had 
received a 6 mg/kg cumulative dose of Am B before 
being shifted to ABLC. 
Nephrotoxicity of Am B alone or in combination 
with another drug was the reason to change in 15 
patients. Out of 15 patients, 14 were initially given 
Am B, which then led to renal impairment with a 
mean creatinine clearance at study entry of 47 ml/min 
(range 18-93 mL/min). Five of these patients received 
concomitant cyclosporin. The last patient initially 
treated with AmB was shifted to ABLC because of 
uncompensatable renal loss of potassium. 
Two patients were considered to be intolerant of 
An1 B, as they presented with high fever and chills 
unresponsive to paracetamol or pethidine when they 
were infused with Am B. They received seven and 
three doses of Am B, respectively, before changing to 
ABLC. 
RESULTS 
The whole group of patients received a mean 
cumulative dose of ABLC of 6107 mg (range 660- 
16 050 mg) over a mean duration of 22 days (range 
4-49 days). The 11 patients with proven invasive 
aspergillosis received a mean total dose of about 
7650 mg (range 910-16 050 mg) of ABLC. The seven 
patients with proven invasive candidosis received a 
mean total dose of 4580 mg (range 660-7350 mg) of 
ABLC. The seven patients with suspected pulmonary 
aspergillosis received a mean total dose of 6525 mg 
(range 1125-14 700 mg) of ABLC. 
Adjuvant surgery was performed in 11 patients. 
Three patients with pulmonary aspergillosis underwent 
resection of the infected lobe. Abscess drainage was 
performed in four patients with Candida sp. abscess 
(peribronchial abscess, spondylodiscitis and two intra- 
abdominal abscesses). The two patients with aspergillar 
sinusitis underwent extensive curettage of their lesions. 
One patient with disseminated aspergillus infection and 
ocular involvement underwent vitrectomy. A partial 
gastrectomy was performed in the patient with gastric 
mucormycosis. 
Our patients recovered from 19 of the 30 episodes 
of fungal infection (63%). Fourteen of the 22 patients 
(patients 1-22) with proven invasive fungal infection 
were successfully treated by ABLC. Survival was 54% 
(6/11) for patients with proven aspergillosis and 71% 
(5/7) for patients with proven candidal infection. 
The survival rate was 57% (4/7) for patients with 
suspected aspergillosis. Eleven patients died. Necropsy 
was performed in seven cases, and showed that the 
death was due to invasive aspergillosis in four cases and 
to underlying disease in three cases. The four other 
patients were not autopsied. Among them, one patient 
with disseminated aspergdlosis (patient 2), and one 
patient with digestive mucormycosis (patient 22) clearly 
died &om progression of their fungal infection, while 
patient 12 with candidemia &ed h-om cardiac failure, 
and the last (patient 27) death remained unexplained. 
Twenty-three episodes were mycologically docu- 
mented: 11 proven invasive aspergillosis (1-1 l) ,  one 
suspected invasive aspergdlosis (23), seven candidal 
infections (12-1 8), one cryptococcal meningitis, one 
fusaremia, one Geotrichum angiocholitis and one 
digestive mucormycosis. Twenty patients were myco- 
logically evaluable at the end of treatment. Aspergillus 
was eradicated in two of 11 patient, persisted in nine of 
11 patient and was not evaluable in one patient. Candida 
was eradicated in three of five patients, persisted in two 
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of five patients, and was not evaluable in 2 patients. 
Geotrichum and Fusarium were eradicated, while Crypto- 
coccus neOfrrnans and Mucor persisted. For proven 
aspergillosis and proven candidosis, corresponding rates 
were 20% (2/10), and 60% (3/5), respectively. For all 
the proven and evaluable fungal infections, the myco- 
logical eradication rate was 37% (7/19). 
Safety of study drug 
Tolerance of ABLC was good: nine patients did not 
develop any side effect during treatment. Eighteen 
patients presented one or more side effects attributed 
to ABLC. Eleven patients developed fever and chills 
during infusion. These reactions were easily controlled 
by administration of low doses of corticosteroids, 
paracetamol or pethidine, and slowing the speed of the 
infusion. Of the two patients shifted to ABLC because 
of fever and chills when receiving Am B, one presented 
the acute infusion syndrome while the other &d not. 
One patient developed transient severe hypotension 
during the first infusion of ABLC. 
In one patient on an anticoumarinic drug, a 
transient increase of the dose of the anticoumarinic 
drug was needed during ABLC treatment; the same 
patient had increased amylase and lipase during treat- 
ment. In t h s  patient, these modifications were possibly 
related to the drug. Severe hepatic dysfunction marked 
by coagulopathy was observed at the end of the treat- 
ment in a patient treated with two courses of ABLC for 
a total dose of 14 g (patients 17 and 29). Coagulation 
normalized after discontinuation of the drug. 
Fourteen courses (50%) were complicated by 
decline of renal function during ABLC treatment, 
necessitating a transient reduction of the drug dosage. 
The mean increase of serum creatinine was 89% 
(26-237%) compared to the lowest serum creatinine 
obtained at entry or during treatment for a particular 
patient. Patient 13 had only an 11% increase but was 
considered for lowering the dose, as he was a kidney 
transplant recipient with a baseline creatinine clearance 
of 32 rnL/min. Patient 9 had a 200% increase of serum 
creatinine compared to baseline, but, as he suffered 
severe invasive aspergillosis, the drug dosage was not 
modified. For these 14 patients, reason to treat with 
ABLC, mean cumulative dose, and renal clearance 
(cl cr) at entry and study end were as follows: failure 
of Am B, three patients; mean dose 5630 mg; cl cr 
72 mL/min and 63 mL/min; nephrotoxicity of Am B, 
six patients; mean dose 4430 mg; cl cr, 46 ml/min and 
50mLJmin; ABLC first line, 5 patients; mean dose 
9237 mg, cl cr, 90 mL/min and 50 d / m i n .  
In contrast, of the 15 patients given ABLC because 
of nephrotoxicity of Am B alone or combined with 
another drug, 10 patients did not experience further 
nephrotoxicity. Eight of 10 of these patients (patients 
6, 10, 20, 22, 23, 25, 26) received more than 7 days 
of treatment (mean cumulative dose 5750 mg, range 
1250-1 1 185 mg) with a creatinine clearance of 60 d/ 
min at baseline and 68 ml/min at study end, respec- 
tively. The two other patients (patients 3 and 7) with 
7 days of treatment were not evahated. 
Evolution of creatinine clearance for the whole 
group according to the duration of'therapy is as follows: 
57ml /min  at entry and 56mL/min at 2 weeks 
(11 courses), 66 rnL/min at entry, 69 ml/min at 
2 weeks and 66 d / m i n  at 4 weeks (11 courses), 
and 110 mL/min at entry, 87.5 nL/min at 2 weeks, 
71 mL/min at 4 weeks and 72 rnL/min at 6 weeks 
(three courses) for patients having received 2, 4 and 
6 weeks oE treatment, respectidy. Seven patients 
entering the study with a mean creatinine clearance 
around 30 d / m i n  (mean 33 mL/min, range 18-46 
mL/min) ended the study period with a mean creati- 
nine clearance of 46 ml/min (range 35-77 ml/min). 
No discontinuation of the drug was needed except 
for hepatic insufficiency, and no death was attributable 
to the drug. 
DISCUSSION 
Wie observed an overall clinical response rate of 63%, 
which is in the range of the responses reported in other 
series on treatment of invasive fimgal infections in 
immunocompromised patients [7,8,10,11]. Clinical 
response rate was lower for patients with proven in- 
vasive aspergillosis (54%) than for patients with proven 
invasive candidosis (71%). Patierits with suspected 
invasive aspergiUosis also have a worse prognosis, with 
a 57% survival rate. This is in accordance with the fact 
that invasive aspergillosis is more djflicult to treat than 
invasive candidosis and arises in rnore compromised 
patients. Mean cumulative doses of ABLC reflect the 
same distribution: 7350 mg for patients with proven 
aspergillosis, 6525 mg for patients with suspected 
aspergillosis, and 4580 mg for patients with proven 
invasive candidosis. This mirrors the perceived gravity 
of the disease and the willingness (of the physician to 
care more aggressively for patients with aspergillosis. 
However, in our small series, unexpectedly, patients 
with invasive aspergillosis were less likely to suffer side 
effects of ABLC than patients with invasive candidosis. 
The global mycologic response of 37% for proven 
and evaluable fungal infection is lower than that found 
in other studies [7,8]. This could be due to the high 
rate of aspergillus infection, with an eradication rate of 
only two of 10 (20%). This low rate could be due to 
the small size of the series. 
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The analysis of data is difficult in this small patient 
population receiving the drug on a compassionate use 
basis. Our diagnostic and outcome criteria can also be 
criticized [12]. In this compassionate study, hetero- 
geneous adaptation of drug dosage was performed in 
response to various magnitudes of decreased renal 
function. The threshold level of creatinine clearance to 
modift the dose of ABLC balanced an acceptable 
degree of nephrotoxicity against the severity of the 
fungal disease. Renal dysfunction due to pretreatment 
with Am B which can last several months 121 further 
complicates the analysis of renal function in this study. 
Nevertheless, ABLC enabled us to treat a group of 
patients with suspected or proven invasive mycosis who 
were or would have been incapable of tolerating the 
efficacious dose of conventional amphotericin B. 
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